This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ipratropium bromide nasal

Updated 2 Feb 2023 | Topical nasal decongestants


Nasal spray containing ipratropium bromide

Drugs List

  • ipratropium bromide 21microgram nasal pump spray
  • RINASPRAY 21microgram nasal spray
  • Therapeutic Indications


    Symptomatic relief of rhinorrhoea in allergic and non-allergic rhinitis



    Two sprays (42 micrograms) in each nostril two to three times a day.


    Two sprays (42 micrograms) in each nostril two to three times a day.


    Children 12 to18 years:
    Two sprays (42 micrograms) in each nostril two to three times a day.


    Children under 12 years

    Precautions and Warnings

    Benign prostatic hyperplasia
    Bladder outflow obstruction
    Cystic fibrosis
    Narrow angle glaucoma

    Advise ability to drive/operate machinery may be affected by side effects
    Contains benzalkonium chloride
    Avoid spray in or near eyes

    As patients with cystic fibrosis may be prone to gastro-intestinal motility disturbances, the ipratropium bromide nasal pump spray should be used with caution in these patients.

    Eye pain or discomfort, blurred vision, visual halos or coloured images in association with red eyes from conjunctival congestion and corneal oedema may be signs of acute narrow-angle glaucoma. Should any combination of these symptoms develop, treatment with miotic drops should be initiated and specialist advise sought immediately.

    Pregnancy and Lactation


    Use ipratropium bromide with caution in pregnancy.

    The manufacturer has noted that safety has not been established and that the benefits of using ipratropium bromide during a confirmed or suspected pregnancy must be weighed against the possible hazards to the unborn child. Preclinical studies have shown no embryotoxic or teratogenic effects following inhalation or intranasal application at doses considerably higher than those recommended in man.

    Ipratropium was not teratogenic in mice, rats, and rabbits when administered either orally or by inhalation.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use ipratropium bromide with caution in breastfeeding.

    It is not known whether ipratropium bromide is excreted into breast milk.

    Definitive data on the appearance of atropine in milk has not been published. Ipratropium is lipid insoluble and, similar to other quaternary ammonium bases, may appear in milk.
    It is unlikely that the infant would absorb any ipratropium bromide, due to its poor tissue distribution and oral absorption of this drug. However, caution should be exercised when administered to nursing mothers.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic reaction
    Anaphylactic shock
    Angioedema of tongue, lips and face
    Blurred vision
    Conjunctival hyperaemia
    Corneal oedema
    Disturbances in accommodation
    Dry mouth
    Dry throat
    Dryness and irritation of nose
    Eye pain
    Gastro-intestinal motility disturbances
    Hypersensitivity reactions
    Increased heart rate
    Increased intra-ocular pressure
    Ocular discomfort
    Oropharyngeal oedema
    Supraventricular tachycardia
    Throat irritation
    Urinary retention
    Visual haloes


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: May 2014

    Reference Sources

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press Accessed on May 07, 2014.

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications Accessed on May 7, 2014.

    Medications and Mothers' Milk, 14th Edition (2010) Hale, T. Hale Publishing, Amarillo, Texas.

    Summary of Product Characteristics: Rinaspray 21 micrograms per metered dose, Nasal Spray solution. Sanofi. Revised December 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.